Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Overview
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Companies Involved in Therapeutics Development
Allergan Plc
Brickell Biotech Inc
Gossamer Bio Inc
HEC Pharm Co Ltd
Idorsia Pharmaceutical Ltd
KBP BioSciences Co Ltd
Merck & Co Inc
Novartis AG
Oxagen Ltd
Seelos Therapeutics, Inc.
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Drug Profiles
ACT-774312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADC-3680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBI-5000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fevipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-7026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
litapiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-1092 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8318 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize PTGDR2 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Timapiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Dormant Products
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Discontinued Products
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2019: Gossamer announces data presentations at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2019
Feb 13, 2019: Asthma pill targets airway muscles to decrease attacks
Nov 05, 2018: Novartis provides update on QAW039
Jan 30, 2018: Novartis India granted permission for conduct Of Clinical Trial in India for its Asthma Drug
Dec 14, 2016: Pulmagen Therapeutics announces positive data for ADC3680, a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II study conducted in Japan by partner Teijin Pharma
Sep 28, 2016: Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 Antagonist Timapiprant for the Treatment of Allergic Asthma
Aug 05, 2016: Asthma pill could reduce symptoms in severe sufferers
Feb 17, 2016: Update on Phase 2 clinical trial with OC459 in patients with moderate to severe atopic dermatitis
Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigatiol New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss
Jun 16, 2015: Atopix Therapeutics Secures Funding to Broaden Development of CRTH2 Antagonists for TH2-Mediated Disease
Feb 18, 2015: The US FDA approved KBP-7026 to enter Phase I clinical trial
Aug 01, 2014: Pulmagen’s lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study
Aug 01, 2014: Eleventa has enrolled first patients in Phase III multicenter clinical trial
Jul 28, 2014: Eleventa enrolled the first patients into the multi-center center clinical study of the 3rd phase of antiasthmatic drug
Mar 03, 2014: Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Allergan Plc, H2 2019
Pipeline by Brickell Biotech Inc, H2 2019
Pipeline by Gossamer Bio Inc, H2 2019
Pipeline by HEC Pharm Co Ltd, H2 2019
Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
Pipeline by KBP BioSciences Co Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Oxagen Ltd, H2 2019
Pipeline by Seelos Therapeutics, Inc., H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019